WallStreetZenWallStreetZen

NASDAQ: MRNS
Marinus Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MRNS past revenue growth

How has MRNS's revenue growth performed historically?
Company
21.63%
Industry
148.4%
Market
16.96%
MRNS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MRNS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MRNS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MRNS earnings and revenue history

Current Revenue
$31.0M
Current Earnings
-$141.4M
Current Profit Margin
-456.3%

MRNS Return on Equity

Current Company
-264.6%
Current Industry
-63.5%
Current Market
188%
MRNS's Return on Equity (-264.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MRNS announces earnings.

MRNS Return on Assets

Current Company
-70.7%
Current Industry
2.9%
MRNS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MRNS Return on Capital Employed

Current Company
-96.75%
Current Industry
19.5%
MRNS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MRNS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MRNS$30.99M-$125.31M-$141.41M+257.32%N/A
ONCY$0.00-$20.04M-$20.41MN/AN/A
GRTS$16.34M-$112.80M-$138.49M+68.96%N/A
CGTX$0.00-$25.51M-$25.79MN/AN/A
IFRX$68.58k-$45.72M-$46.38MN/AN/A
View Top Biotech Stocks

MRNS earnings dates

Next earnings date
May 9, 2024

Marinus Pharmaceuticals Earnings & Revenue FAQ

What were MRNS's earnings last quarter?

On Invalid Date, Marinus Pharmaceuticals (NASDAQ: MRNS) reported Q4 2023 earnings per share (EPS) of -$0.74, up 16.85% year over year. Total Marinus Pharmaceuticals earnings for the quarter were -$41.77 million. In the same quarter last year, Marinus Pharmaceuticals's earnings per share (EPS) was -$0.89.

If you're new to stock investing, here's how to buy Marinus Pharmaceuticals stock.

What was MRNS's earnings growth in the past year?

As of Q2 2024, Marinus Pharmaceuticals's earnings has grown year over year. Marinus Pharmaceuticals's earnings in the past year totalled -$141.41 million.

What is MRNS's earnings date?

Marinus Pharmaceuticals's earnings date is Invalid Date. Add MRNS to your watchlist to be reminded of MRNS's next earnings announcement.

What was MRNS's revenue last quarter?

On Invalid Date, Marinus Pharmaceuticals (NASDAQ: MRNS) reported Q4 2023 revenue of $7.19 million up 0.39% year over year. In the same quarter last year, Marinus Pharmaceuticals's revenue was $7.16 million.

What was MRNS's revenue growth in the past year?

As of Q2 2024, Marinus Pharmaceuticals's revenue has grown 21.63% year over year. This is 126.77 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Marinus Pharmaceuticals's revenue in the past year totalled $30.99 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.